Lucid Diagnostics Inc. (LUCD) 10-Year Financial Performance & Capital Metrics

LUCD • • Industrial / General

HealthcareMedical DevicesDiagnostic & Imaging EquipmentPoint-of-Care Diagnostics

AboutLucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Show more

Revenue $4M +79.0%
EBITDA -$45M +2.4%
Net Income -$46M +13.6%
EPS (Diluted) -1.05 +16.7%
Gross Margin -90.2% +63.8%
EBITDA Margin -1032.79% +45.5%
Operating Margin -1059.64% +46.9%
Net Margin -1047.61% +51.7%
ROE -2956.43% -482.0%
ROIC -
Debt/Equity 3.94
Interest Coverage -1771.23 -1419.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 3.9x
✗Negative free cash flow
✗Shares diluted 21.0% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 11.7x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y105.61%

TTM28885.15%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-23193.96%

EPS CAGR

10Y-

5Y-

3Y-

TTM21.08%

ROCE

10Y Avg-632.57%

5Y Avg-632.57%

3Y Avg-799.09%

Latest-1813.43%

Peer Comparison

Point-of-Care Diagnostics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
PAVMPAVmed Inc.	8.06M	8.75	17.64	22.15%	-217914.55%	-245.07%
SMLRSemler Scientific, Inc.	310.75M	20.33	3.96	-17.44%	130.8%	10.51%	0.00
BJDXBluejay Diagnostics, Inc.	1.18M	0.65	-0.02			-185.51%	0.04
HSCSHeartSciences Inc.	10.17M	3.20	-0.34	-76.61%	-1042.38%	-216.05%	14.55
LUCDLucid Diagnostics Inc.	163.87M	1.25	-1.19	79%	-8.6%	-404.1%	3.94
BMRABiomerica, Inc.	8.09M	2.68	-1.24	-1.92%	-90.29%	-90.76%	0.11
MDAISpectral AI, Inc.	49.41M	1.61	-1.89	63.83%	-70.64%
CODXCo-Diagnostics, Inc.	6.12M	2.92	-2.35	-42.53%	-63.36%	-80.8%	0.04

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	500K	377K	2.43M	4.35M
Revenue Growth %	-	-	-	-	-0.25%	5.44%	0.79%
Cost of Goods Sold+	0	0	0	585K	3.61M	8.48M	8.27M
COGS % of Revenue	-	-	-	1.17%	9.59%	3.49%	1.9%
Gross Profit+	0	0	0	-85K	-3.24M	-6.05M	-3.92M
Gross Margin %	-	-	-	-0.17%	-8.59%	-2.49%	-0.9%
Gross Profit Growth %	-	-	-	-	-37.08%	-0.87%	0.35%
Operating Expenses+	1.13M	4.42M	8.28M	27.33M	52.93M	42.43M	42.13M
OpEx % of Revenue	-	-	-	54.67%	140.41%	17.48%	9.69%
Selling, General & Admin	410.29K	958.72K	2.84M	18.04M	39.82M	35.66M	36.62B
SG&A % of Revenue	-	-	-	36.08%	105.62%	14.69%	8425.91%
Research & Development	715.63K	3.46M	5.44M	9.3M	11.47M	7.25M	5.99M
R&D % of Revenue	-	-	-	18.59%	30.41%	2.99%	1.38%
Other Operating Expenses	0	278	0	0	1.65M	-478K	-36.58B
Operating Income+	-1.13M	-4.42M	-8.28M	-27.42M	-56.17M	-48.48M	-46.05M
Operating Margin %	-	-	-	-54.84%	-148.99%	-19.97%	-10.6%
Operating Income Growth %	-	-2.93%	-0.87%	-2.31%	-1.05%	0.14%	0.05%
EBITDA+	563K	0	0	-27.41M	-54.23M	-45.98M	-44.88M
EBITDA Margin %	-	-	-	-54.83%	-143.86%	-18.94%	-10.33%
EBITDA Growth %	-	-1%	-	-	-0.98%	0.15%	0.02%
D&A (Non-Cash Add-back)	1.69M	4.42M	8.28M	4K	1.94M	2.5M	1.17M
EBIT	-1.13M	-4.42M	-8.28M	-27.42M	-56.17M	-52.25M	-45.5M
Net Interest Income+	0	0	0	-659K	80K	8K	296K
Interest Income	0	0	0	0	88K	424K	322K
Interest Expense	0	0	0	659K	8K	416K	26K
Other Income/Expense	0	0	0	-659K	0	-4.18M	523K
Pretax Income+	-1.13M	-4.42M	-8.28M	-28.08M	-56.17M	-52.67M	-45.53M
Pretax Margin %	-	-	-	-56.16%	-148.99%	-21.69%	-10.48%
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.13M	-4.42M	-8.28M	-28.08M	-56.17M	-52.67M	-45.53M
Net Margin %	-	-	-	-56.16%	-148.99%	-21.69%	-10.48%
Net Income Growth %	-	-2.93%	-0.87%	-2.39%	-1%	0.06%	0.14%
Net Income (Continuing)	-1.13M	-4.42M	-8.28M	-28.08M	-56.17M	-52.67M	-45.53M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.03	-0.12	-0.22	-0.78	-1.55	-1.26	-1.05
EPS Growth %	-	-2.95%	-0.83%	-2.55%	-0.99%	0.19%	0.17%
EPS (Basic)	-0.03	-0.12	-0.22	-0.78	-1.55	-1.26	-1.05
Diluted Shares Outstanding	36.99M	36.99M	36.99M	36.06M	36.17M	41.76M	50.52M
Basic Shares Outstanding	36.99M	36.99M	36.99M	36.06M	36.17M	41.76M	50.52M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.8K	390.9K	1.44M	57.3M	24.36M	22.07M	25.15M
Cash & Short-Term Investments	17.8K	156.4K	111K	53.66M	22.47M	18.9M	22.36M
Cash Only	17.8K	156.4K	111K	53.66M	22.47M	18.9M	22.36M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	200K	17K	45K	405K
Days Sales Outstanding	-	-	-	146	16.46	6.76	34.01
Inventory	0	0	834K	493K	111K	278K	341K
Days Inventory Outstanding	-	-	-	307.6	11.21	11.97	15.06
Other Current Assets	0	118.09K	0	0	0	1.98M	0
Total Non-Current Assets+	0	643K	755K	1.7M	8.15M	5.2M	5.57M
Property, Plant & Equipment	0	0	0	971K	3.6M	2.64M	3.7M
Fixed Asset Turnover	-	-	-	0.51x	0.10x	0.92x	1.17x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	3.44M	1.42M	736K
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	643K	755K	725K	1.11M	1.13M	1.13M
Total Assets+	17.8K	1.03M	2.19M	59M	32.51M	27.27M	30.71M
Asset Turnover	-	-	-	0.01x	0.01x	0.09x	0.14x
Asset Growth %	-	57.08%	1.12%	25.88%	-0.45%	-0.16%	0.13%
Total Current Liabilities+	1.08M	6.34M	15.71M	4.26M	8.43M	29.38M	23.52M
Accounts Payable	497.23K	799.08K	2.06M	1.49M	1.06M	1.15M	1.24M
Days Payables Outstanding	-	-	-	929.66	106.65	49.34	54.8
Short-Term Debt	0	0	0	0	0	13.95M	18.6M
Deferred Revenue (Current)	0	0	0	0	0	936K	0
Other Current Liabilities	583.26K	5.32M	0	557K	5.53M	791K	1.35M
Current Ratio	0.02x	0.06x	0.09x	13.45x	2.89x	0.75x	1.07x
Quick Ratio	0.02x	0.06x	0.04x	13.34x	2.88x	0.74x	1.05x
Cash Conversion Cycle	-	-	-	-476.06	-78.98	-30.6	-5.73
Total Non-Current Liabilities+	0	0	0	0	1.04M	199K	1.8M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.04M	199K	1.8M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	1.08M	6.34M	15.71M	4.26M	9.46M	29.58M	25.32M
Total Debt+	0	0	0	0	2M	15.26M	21.25M
Net Debt	-17.8K	-156.4K	-111K	-53.66M	-20.48M	-3.64M	-1.1M
Debt / Equity	-	-	-	-	0.09x	-	3.94x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-0.03x	-	-	-	-	-	-
Interest Coverage	-	-	-	-41.61x	-7021.38x	-116.54x	-1771.23x
Total Equity+	-1.06M	-5.31M	-13.52M	54.74M	23.05M	-2.31M	5.39M
Equity Growth %	-	-4%	-1.55%	5.05%	-0.58%	-1.1%	3.33%
Book Value per Share	-0.03	-0.14	-0.37	1.52	0.64	-0.06	0.11
Total Shareholders' Equity	-1.06M	-5.31M	-13.52M	54.74M	23.05M	-2.31M	5.39M
Common Stock	10K	14.11K	14K	35K	41K	42K	63K
Retained Earnings	-1.13M	-5.55M	-13.83M	-41.9M	-98.08M	-150.74M	-203.77M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-113.7K	-2.36M	-5.63M	-17.67M	-29.68M	-32.82M	-44.14M
Operating CF Margin %	-	-	-	-35.34%	-78.74%	-13.52%	-10.16%
Operating CF Growth %	-	-19.77%	-1.38%	-2.14%	-0.68%	-0.11%	-0.35%
Net Income	-1.13M	-4.42M	-8.28M	-28.08M	-56.17M	-52.67M	-45.53M
Depreciation & Amortization	0	0	0	4K	1.94M	2.5M	1.17M
Stock-Based Compensation	79.85K	0	65K	0	14.99M	6.82M	4.53M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	-205.06K	173.94K	459	9.6M	653K	4.85M	119K
Working Capital Changes	720.05K	1.89M	2.59M	807K	8.91M	5.67M	-4.43M
Change in Receivables	0	0	0	-200K	183K	-28K	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	497.23K	301.85K	1.15M	-665K	-445K	89K	96K
Cash from Investing+	0	0	0	-862K	-4.11M	-221K	-646K
Capital Expenditures	0	0	0	-862K	-908K	-221K	-296K
CapEx % of Revenue	-	-	-	1.72%	2.41%	0.09%	0.07%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-3.2M	0	-350K
Cash from Financing+	131.5K	2.5M	5.58M	72.08M	2.61M	29.46M	48.25M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	131.5K	0	0	-5.66M	804K	551K	451K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-113.7K	-2.36M	-5.63M	-18.53M	-30.59M	-33.04M	-44.79M
FCF Margin %	-	-	-	-37.06%	-81.15%	-13.61%	-10.31%
FCF Growth %	-	-19.77%	-1.38%	-2.29%	-0.65%	-0.08%	-0.36%
FCF per Share	-0.00	-0.06	-0.15	-0.51	-0.85	-0.79	-0.89
FCF Conversion (FCF/Net Income)	0.10x	0.53x	0.68x	0.63x	0.53x	0.62x	0.97x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-136.23%	-144.42%	-507.97%	-2956.43%
Return on Invested Capital (ROIC)	-	-	-	-	-2305.24%	-	-
Gross Margin	-	-	-	-17%	-858.62%	-249.18%	-90.2%
Net Margin	-	-	-	-5615.6%	-14899.47%	-2169.11%	-1047.61%
Debt / Equity	-	-	-	-	0.09x	-	3.94x
Interest Coverage	-	-	-	-41.61x	-7021.38x	-116.54x	-1771.23x
FCF Conversion	0.10x	0.53x	0.68x	0.63x	0.53x	0.62x	0.97x
Revenue Growth	-	-	-	-	-24.6%	544.03%	79%

Frequently Asked Questions

Growth & Financials

Lucid Diagnostics Inc. (LUCD) reported $1.21B in revenue for fiscal year 2024.

Lucid Diagnostics Inc. (LUCD) grew revenue by 79.0% over the past year. This is strong growth.

Lucid Diagnostics Inc. (LUCD) reported a net loss of $10.44B for fiscal year 2024.

Dividend & Returns

Lucid Diagnostics Inc. (LUCD) has a return on equity (ROE) of -2956.4%. Negative ROE indicates the company is unprofitable.

Lucid Diagnostics Inc. (LUCD) had negative free cash flow of $44.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Lucid Diagnostics Inc. (LUCD) 10-Year Financial Performance & Capital Metrics

LUCD • • Industrial / General

HealthcareMedical DevicesDiagnostic & Imaging EquipmentPoint-of-Care Diagnostics

Revenue $4M +79.0%
EBITDA -$45M +2.4%
Net Income -$46M +13.6%
EPS (Diluted) -1.05 +16.7%
Gross Margin -90.2% +63.8%
EBITDA Margin -1032.79% +45.5%
Operating Margin -1059.64% +46.9%
Net Margin -1047.61% +51.7%
ROE -2956.43% -482.0%
ROIC -
Debt/Equity 3.94
Interest Coverage -1771.23 -1419.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 3.9x
✗Negative free cash flow
✗Shares diluted 21.0% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 11.7x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y105.61%

TTM28885.15%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-23193.96%

EPS CAGR

10Y-

5Y-

3Y-

TTM21.08%

ROCE

10Y Avg-632.57%

5Y Avg-632.57%

3Y Avg-799.09%

Latest-1813.43%

Peer Comparison

Point-of-Care Diagnostics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
PAVMPAVmed Inc.	8.06M	8.75	17.64	22.15%	-217914.55%	-245.07%
SMLRSemler Scientific, Inc.	310.75M	20.33	3.96	-17.44%	130.8%	10.51%	0.00
BJDXBluejay Diagnostics, Inc.	1.18M	0.65	-0.02			-185.51%	0.04
HSCSHeartSciences Inc.	10.17M	3.20	-0.34	-76.61%	-1042.38%	-216.05%	14.55
LUCDLucid Diagnostics Inc.	163.87M	1.25	-1.19	79%	-8.6%	-404.1%	3.94
BMRABiomerica, Inc.	8.09M	2.68	-1.24	-1.92%	-90.29%	-90.76%	0.11
MDAISpectral AI, Inc.	49.41M	1.61	-1.89	63.83%	-70.64%
CODXCo-Diagnostics, Inc.	6.12M	2.92	-2.35	-42.53%	-63.36%	-80.8%	0.04

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	500K	377K	2.43M	4.35M
Revenue Growth %	-	-	-	-	-0.25%	5.44%	0.79%
Cost of Goods Sold+	0	0	0	585K	3.61M	8.48M	8.27M
COGS % of Revenue	-	-	-	1.17%	9.59%	3.49%	1.9%
Gross Profit+	0	0	0	-85K	-3.24M	-6.05M	-3.92M
Gross Margin %	-	-	-	-0.17%	-8.59%	-2.49%	-0.9%
Gross Profit Growth %	-	-	-	-	-37.08%	-0.87%	0.35%
Operating Expenses+	1.13M	4.42M	8.28M	27.33M	52.93M	42.43M	42.13M
OpEx % of Revenue	-	-	-	54.67%	140.41%	17.48%	9.69%
Selling, General & Admin	410.29K	958.72K	2.84M	18.04M	39.82M	35.66M	36.62B
SG&A % of Revenue	-	-	-	36.08%	105.62%	14.69%	8425.91%
Research & Development	715.63K	3.46M	5.44M	9.3M	11.47M	7.25M	5.99M
R&D % of Revenue	-	-	-	18.59%	30.41%	2.99%	1.38%
Other Operating Expenses	0	278	0	0	1.65M	-478K	-36.58B
Operating Income+	-1.13M	-4.42M	-8.28M	-27.42M	-56.17M	-48.48M	-46.05M
Operating Margin %	-	-	-	-54.84%	-148.99%	-19.97%	-10.6%
Operating Income Growth %	-	-2.93%	-0.87%	-2.31%	-1.05%	0.14%	0.05%
EBITDA+	563K	0	0	-27.41M	-54.23M	-45.98M	-44.88M
EBITDA Margin %	-	-	-	-54.83%	-143.86%	-18.94%	-10.33%
EBITDA Growth %	-	-1%	-	-	-0.98%	0.15%	0.02%
D&A (Non-Cash Add-back)	1.69M	4.42M	8.28M	4K	1.94M	2.5M	1.17M
EBIT	-1.13M	-4.42M	-8.28M	-27.42M	-56.17M	-52.25M	-45.5M
Net Interest Income+	0	0	0	-659K	80K	8K	296K
Interest Income	0	0	0	0	88K	424K	322K
Interest Expense	0	0	0	659K	8K	416K	26K
Other Income/Expense	0	0	0	-659K	0	-4.18M	523K
Pretax Income+	-1.13M	-4.42M	-8.28M	-28.08M	-56.17M	-52.67M	-45.53M
Pretax Margin %	-	-	-	-56.16%	-148.99%	-21.69%	-10.48%
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.13M	-4.42M	-8.28M	-28.08M	-56.17M	-52.67M	-45.53M
Net Margin %	-	-	-	-56.16%	-148.99%	-21.69%	-10.48%
Net Income Growth %	-	-2.93%	-0.87%	-2.39%	-1%	0.06%	0.14%
Net Income (Continuing)	-1.13M	-4.42M	-8.28M	-28.08M	-56.17M	-52.67M	-45.53M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.03	-0.12	-0.22	-0.78	-1.55	-1.26	-1.05
EPS Growth %	-	-2.95%	-0.83%	-2.55%	-0.99%	0.19%	0.17%
EPS (Basic)	-0.03	-0.12	-0.22	-0.78	-1.55	-1.26	-1.05
Diluted Shares Outstanding	36.99M	36.99M	36.99M	36.06M	36.17M	41.76M	50.52M
Basic Shares Outstanding	36.99M	36.99M	36.99M	36.06M	36.17M	41.76M	50.52M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.8K	390.9K	1.44M	57.3M	24.36M	22.07M	25.15M
Cash & Short-Term Investments	17.8K	156.4K	111K	53.66M	22.47M	18.9M	22.36M
Cash Only	17.8K	156.4K	111K	53.66M	22.47M	18.9M	22.36M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	200K	17K	45K	405K
Days Sales Outstanding	-	-	-	146	16.46	6.76	34.01
Inventory	0	0	834K	493K	111K	278K	341K
Days Inventory Outstanding	-	-	-	307.6	11.21	11.97	15.06
Other Current Assets	0	118.09K	0	0	0	1.98M	0
Total Non-Current Assets+	0	643K	755K	1.7M	8.15M	5.2M	5.57M
Property, Plant & Equipment	0	0	0	971K	3.6M	2.64M	3.7M
Fixed Asset Turnover	-	-	-	0.51x	0.10x	0.92x	1.17x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	3.44M	1.42M	736K
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	643K	755K	725K	1.11M	1.13M	1.13M
Total Assets+	17.8K	1.03M	2.19M	59M	32.51M	27.27M	30.71M
Asset Turnover	-	-	-	0.01x	0.01x	0.09x	0.14x
Asset Growth %	-	57.08%	1.12%	25.88%	-0.45%	-0.16%	0.13%
Total Current Liabilities+	1.08M	6.34M	15.71M	4.26M	8.43M	29.38M	23.52M
Accounts Payable	497.23K	799.08K	2.06M	1.49M	1.06M	1.15M	1.24M
Days Payables Outstanding	-	-	-	929.66	106.65	49.34	54.8
Short-Term Debt	0	0	0	0	0	13.95M	18.6M
Deferred Revenue (Current)	0	0	0	0	0	936K	0
Other Current Liabilities	583.26K	5.32M	0	557K	5.53M	791K	1.35M
Current Ratio	0.02x	0.06x	0.09x	13.45x	2.89x	0.75x	1.07x
Quick Ratio	0.02x	0.06x	0.04x	13.34x	2.88x	0.74x	1.05x
Cash Conversion Cycle	-	-	-	-476.06	-78.98	-30.6	-5.73
Total Non-Current Liabilities+	0	0	0	0	1.04M	199K	1.8M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.04M	199K	1.8M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	1.08M	6.34M	15.71M	4.26M	9.46M	29.58M	25.32M
Total Debt+	0	0	0	0	2M	15.26M	21.25M
Net Debt	-17.8K	-156.4K	-111K	-53.66M	-20.48M	-3.64M	-1.1M
Debt / Equity	-	-	-	-	0.09x	-	3.94x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-0.03x	-	-	-	-	-	-
Interest Coverage	-	-	-	-41.61x	-7021.38x	-116.54x	-1771.23x
Total Equity+	-1.06M	-5.31M	-13.52M	54.74M	23.05M	-2.31M	5.39M
Equity Growth %	-	-4%	-1.55%	5.05%	-0.58%	-1.1%	3.33%
Book Value per Share	-0.03	-0.14	-0.37	1.52	0.64	-0.06	0.11
Total Shareholders' Equity	-1.06M	-5.31M	-13.52M	54.74M	23.05M	-2.31M	5.39M
Common Stock	10K	14.11K	14K	35K	41K	42K	63K
Retained Earnings	-1.13M	-5.55M	-13.83M	-41.9M	-98.08M	-150.74M	-203.77M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-113.7K	-2.36M	-5.63M	-17.67M	-29.68M	-32.82M	-44.14M
Operating CF Margin %	-	-	-	-35.34%	-78.74%	-13.52%	-10.16%
Operating CF Growth %	-	-19.77%	-1.38%	-2.14%	-0.68%	-0.11%	-0.35%
Net Income	-1.13M	-4.42M	-8.28M	-28.08M	-56.17M	-52.67M	-45.53M
Depreciation & Amortization	0	0	0	4K	1.94M	2.5M	1.17M
Stock-Based Compensation	79.85K	0	65K	0	14.99M	6.82M	4.53M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	-205.06K	173.94K	459	9.6M	653K	4.85M	119K
Working Capital Changes	720.05K	1.89M	2.59M	807K	8.91M	5.67M	-4.43M
Change in Receivables	0	0	0	-200K	183K	-28K	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	497.23K	301.85K	1.15M	-665K	-445K	89K	96K
Cash from Investing+	0	0	0	-862K	-4.11M	-221K	-646K
Capital Expenditures	0	0	0	-862K	-908K	-221K	-296K
CapEx % of Revenue	-	-	-	1.72%	2.41%	0.09%	0.07%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-3.2M	0	-350K
Cash from Financing+	131.5K	2.5M	5.58M	72.08M	2.61M	29.46M	48.25M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	131.5K	0	0	-5.66M	804K	551K	451K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-113.7K	-2.36M	-5.63M	-18.53M	-30.59M	-33.04M	-44.79M
FCF Margin %	-	-	-	-37.06%	-81.15%	-13.61%	-10.31%
FCF Growth %	-	-19.77%	-1.38%	-2.29%	-0.65%	-0.08%	-0.36%
FCF per Share	-0.00	-0.06	-0.15	-0.51	-0.85	-0.79	-0.89
FCF Conversion (FCF/Net Income)	0.10x	0.53x	0.68x	0.63x	0.53x	0.62x	0.97x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-136.23%	-144.42%	-507.97%	-2956.43%
Return on Invested Capital (ROIC)	-	-	-	-	-2305.24%	-	-
Gross Margin	-	-	-	-17%	-858.62%	-249.18%	-90.2%
Net Margin	-	-	-	-5615.6%	-14899.47%	-2169.11%	-1047.61%
Debt / Equity	-	-	-	-	0.09x	-	3.94x
Interest Coverage	-	-	-	-41.61x	-7021.38x	-116.54x	-1771.23x
FCF Conversion	0.10x	0.53x	0.68x	0.63x	0.53x	0.62x	0.97x
Revenue Growth	-	-	-	-	-24.6%	544.03%	79%

Frequently Asked Questions

Growth & Financials

Lucid Diagnostics Inc. (LUCD) reported $1.21B in revenue for fiscal year 2024.

Lucid Diagnostics Inc. (LUCD) grew revenue by 79.0% over the past year. This is strong growth.

Lucid Diagnostics Inc. (LUCD) reported a net loss of $10.44B for fiscal year 2024.

Dividend & Returns

Lucid Diagnostics Inc. (LUCD) has a return on equity (ROE) of -2956.4%. Negative ROE indicates the company is unprofitable.

Lucid Diagnostics Inc. (LUCD) had negative free cash flow of $44.2M in fiscal year 2024, likely due to heavy capital investments.